SIRT1 in cardiovascular aging

Clinica Chimica Acta

Volumn 437, Issue , 2014, Pages 106-114

  Luo, Xin Yuan ^a   Qu, Shun Lin ^a   Tang, Zhi Han ^a   Zhang, Yuan ^a   Liu, Mi Hua ^a   Peng, Juan ^a   Tang, Hui ^a   Yu, Kang Lun ^a   Zhang, Chi ^a   Ren, Zhong ^a   Jiang, Zhi Sheng ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Anti aging strategies; Autophagy; Cardiovascular aging; Inflammation; Oxidative stress; SIRT1

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; P66SHC PROTEIN; PROTEIN SHC; SIRTUIN 1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; SIRT1 PROTEIN, HUMAN;

AGING; AUTOPHAGY; AUTOPHAGY RELATED GENE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; GENE; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AGING; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; OXIDATIVE STRESS; SIRTUIN 1;

EID: 84905267064     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.07.019     Document Type: Review

References (131)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
2. Heidenreich P.A., Trogdon J.G., Khavjou O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
3. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation 2003, 107:346-354.
4. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
5. Jin K. Modern biological theories of aging. Aging Dis 2010, 1:72-74.
6. Cefalu C.A. Theories and mechanisms of aging. Clin Geriatr Med 2011, 27:491-506.
7. Dai D.F., Rabinovitch P.S., Ungvari Z. Mitochondria and cardiovascular aging. Circ Res 2012, 110:1109-1124.
8. Nair S., Ren J. Autophagy and cardiovascular aging: lesson learned from rapamycin. Cell Cycle 2012, 11:2092-2099.
9. Wang Y., Xu C., Liang Y., Vanhoutte P.M. SIRT1 in metabolic syndrome: where to target matters. Pharmacol Ther 2012, 136:305-318.
10. Rahman S., Islam R. Mammalian Sirt1: insights on its biological functions. Cell Commun Signal 2011, 9:11.
11. Chong Z.Z., Wang S., Shang Y.C., Maiese K. Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol 2012, 8:89-100.
12. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
13. Frye R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999, 260:273-279.
14. Smith J.S., Boeke J.D. An unusual form of transcriptional silencing in yeast ribosomal DNA. Genes Dev 1997, 11:241-254.
15. Kaeberlein M., McVey M., Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999, 13:2570-2580.
16. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000, 273:793-798.
17. Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005, 16:4623-4635.
18. McBurney M.W., Yang X., Jardine K., Bieman M., Th'ng J., Lemieux M. The absence of SIR2alpha protein has no effect on global gene silencing in mouse embryonic stem cells. Mol Cancer Res 2003, 1:402-409.
19. +-dependent histone deacetylase SIRT1. J Biol Chem 2007, 282:6823-6832.
20. Pan M., Yuan H., Brent M., Ding E.C., Marmorstein R. SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity. J Biol Chem 2012, 287:2468-2476.
21. Flick F., Luscher B. Regulation of sirtuin function by posttranslational modifications. Front Pharmacol 2012, 3:29.
22. Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P., Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004, 16:93-105.
23. Alcendor R.R., Gao S., Zhai P., et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007, 100:1512-1521.
24. Hsu C.P., Odewale I., Alcendor R.R., Sadoshima J. Sirt1 protects the heart from aging and stress. Biol Chem 2008, 389:221-231.
25. Hsu C.P., Zhai P., Yamamoto T., et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 2010, 122:2170-2182.
26. Vinciguerra M., Santini M.P., Claycomb W.C., Ladurner A.G., Rosenthal N. Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity. Aging (Albany NY) 2010, 2:43-62.
27. Chen C.J., Yu W., Fu Y.C., Wang X., Li J.L., Wang W. Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun 2009, 378:389-393.
28. Zhang Q.J., Wang Z., Chen H.Z., et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008, 80:191-199.
29. Csiszar A., Labinskyy N., Jimenez R., et al. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech Ageing Dev 2009, 130:518-527.
30. Csiszar A., Labinskyy N., Podlutsky A., et al. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008, 294:H2721-H2735.
31. Mattagajasingh I., Kim C.S., Naqvi A., et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2007, 104:14855-14860.
32. Stein S., Lohmann C., Schafer N., et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 2010, 31:2301-2309.
33. Takemura A., Iijima K., Ota H., et al. Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011, 31:2054-2062.
34. Potente M., Ghaeni L., Baldessari D., et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007, 21:2644-2658.
35. Balestrieri M.L., Rienzo M., Felice F., et al. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochim Biophys Acta 2008, 1784:936-945.
36. Oellerich M.F., Potente M. FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ Res 2012, 110:1238-1251.
37. Ota H., Akishita M., Eto M., Iijima K., Kaneki M., Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007, 43:571-579.
38. Zu Y., Liu L., Lee M.Y., et al. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 2010, 106:1384-1393.
39. Zarzuelo M.J., Lopez-Sepulveda R., Sanchez M., et al. SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging. Biochem Pharmacol 2013, 85:1288-1296.
40. Donato A.J., Magerko K.A., Lawson B.R., Durrant J.R., Lesniewski L.A., Seals D.R. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol 2011, 589:4545-4554.
41. El Assar M., Angulo J., Rodriguez-Manas L. Oxidative stress and vascular inflammation in aging. Free Radic Biol Med 2013, 65:380-401.
42. Salminen A., Kaarniranta K., Kauppinen A. Crosstalk between oxidative stress and SIRT1: impact on the aging process. Int J Mol Sci 2013, 14:3834-3859.
43. Xie J., Zhang X., Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res 2013, 67:60-67.
44. Salminen A., Kaarniranta K. SIRT1: regulation of longevity via autophagy. Cell Signal 2009, 21:1356-1360.
45. Chong Z.Z., Li F., Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 2005, 49:1-21.
46. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956, 11:298-300.
47. Muscari C., Giaccari A., Giordano E., Clo C., Guarnieri C., Caldarera C.M. Role of reactive oxygen species in cardiovascular aging. Mol Cell Biochem 1996, 160-161:159-166.
48. Ungvari Z., Buffenstein R., Austad S.N., Podlutsky A., Kaley G., Csiszar A. Oxidative stress in vascular senescence: lessons from successfully aging species. Front Biosci 2008, 13:5056-5070.
49. Salih D.A., Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 2008, 20:126-136.
50. van den Berg M.C., Burgering B.M. Integrating opposing signals toward Forkhead box O. Antioxid Redox Signal 2011, 14:607-621.
51. Sedding D.G. FoxO transcription factors in oxidative stress response and ageing - a new fork on the way to longevity?. Biol Chem 2008, 389:279-283.
52. van der Horst A., Tertoolen L.G., de Vries-Smits L.M., Frye R.A., Medema R.H., Burgering B.M. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 2004, 279:28873-28879.
53. Kobayashi Y., Furukawa-Hibi Y., Chen C., et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 2005, 16:237-243.
54. Brunet A., Sweeney L.B., Sturgill J.F., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
55. Daitoku H., Hatta M., Matsuzaki H., et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci U S A 2004, 101:10042-10047.
56. Tanno M., Kuno A., Yano T., et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 2010, 285:8375-8382.
57. Mortuza R., Chen S., Feng B., Sen S., Chakrabarti S. High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS ONE 2013, 8:e54514.
58. Suo R., Zhao Z.Z., Tang Z.H., et al. Hydrogen sulfide prevents H(2)O(2)-induced senescence in human umbilical vein endothelial cells through SIRT1 activation. Mol Med Rep 2013, 7:1865-1870.
59. Zhang Y., Tang Z.H., Ren Z., et al. Hydrogen sulfide, the next potent preventive and therapeutic agent in aging and age-associated diseases. Mol Cell Biol 2013, 33:1104-1113.
60. Qian J., Fulton D. Post-translational regulation of endothelial nitric oxide synthase in vascular endothelium. Front Physiol 2013, 4:347.
61. Collins C., Tzima E. Hemodynamic forces in endothelial dysfunction and vascular aging. Exp Gerontol 2011, 46:185-188.
62. Ungvari Z., Kaley G., de Cabo R., Sonntag W.E., Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 2010, 65:1028-1041.
63. Schmitt C.A., Heiss E.H., Dirsch V.M. Effect of resveratrol on endothelial cell function: molecular mechanisms. Biofactors 2010, 36:342-349.
64. Xia N., Strand S., Schlufter F., et al. Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide 2013, 32:29-35.
65. Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002, 105:1541-1544.
66. Vasa M., Breitschopf K., Zeiher A.M., Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res 2000, 87:540-542.
67. Hayashi T., Matsui-Hirai H., Miyazaki-Akita A., et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A 2006, 103:17018-17023.
68. Menghini R., Casagrande V., Cardellini M., et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009, 120:1524-1532.
69. Bonfini L., Migliaccio E., Pelicci G., Lanfrancone L., Pelicci P.G. Not all Shc's roads lead to Ras. Trends Biochem Sci 1996, 21:257-261.
70. Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005, 122:221-233.
71. Camici G.G., Schiavoni M., Francia P., et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A 2007, 104:5217-5222.
72. shc gene protects against age-related endothelial dysfunction. Circulation 2004, 110:2889-2895.
73. shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999, 402:309-313.
74. Chen H.Z., Wan Y.Z., Liu D.P. Cross-talk between SIRT1 and p66Shc in vascular diseases. Trends Cardiovasc Med 2013, 23:237-241.
75. Zhou S., Chen H.Z., Wan Y.Z., et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 2011, 109:639-648.
76. Chen H., Wan Y., Zhou S., et al. Endothelium-specific SIRT1 overexpression inhibits hyperglycemia-induced upregulation of vascular cell senescence. Sci China Life Sci 2012, 55:467-473.
77. Franceschi C., Bonafe M., Valensin S., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:244-254.
78. Csiszar A., Ungvari Z., Koller A., Edwards J.G., Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J 2003, 17:1183-1185.
79. Wang M., Zhang J., Jiang L.Q., et al. Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension 2007, 50:219-227.
80. Vasto S., Candore G., Balistreri C.R., et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 2007, 128:83-91.
81. Hoesel B., Schmid J.A. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013, 12:86.
82. Csiszar A., Wang M., Lakatta E.G., Ungvari Z. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol (1985) 2008, 105:1333-1341.
83. Yeung F., Hoberg J.E., Ramsey C.S., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23:2369-2380.
84. Stein S., Matter C.M. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011, 10:640-647.
85. Zeng H.T., Fu Y.C., Yu W., et al. SIRT1 prevents atherosclerosis via liver-X-receptor and NF-κB signaling in a U937 cell model. Mol Med Rep 2013, 8:23-28.
86. Yang L., Zhang J., Yan C., et al. SIRT1 regulates CD40 expression induced by TNF-alpha via NF-κB pathway in endothelial cells. Cell Physiol Biochem 2012, 30:1287-1298.
87. Yang S.R., Wright J., Bauter M., Seweryniak K., Kode A., Rahman I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol 2007, 292:L567-L576.
88. Zhu X., Liu Q., Wang M., et al. Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS ONE 2011, 6:e27081.
89. Yang H., Zhang W., Pan H., et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kappaB activity. PLoS ONE 2012, 7:e46364.
90. Schonthaler H.B., Guinea-Viniegra J., Wagner E.F. Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis 2011, 70(Suppl. 1):i109-i112.
91. Gao Z., Ye J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun 2008, 376:793-796.
92. Vries R.G., Prudenziati M., Zwartjes C., Verlaan M., Kalkhoven E., Zantema A. A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300. EMBO J 2001, 20:6095-6103.
93. Zhang R., Chen H.Z., Liu J.J., et al. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem 2010, 285:7097-7110.
94. Kim J.W., No J.K., Ikeno Y., et al. Age-related changes in redox status of rat serum. Arch Gerontol Geriatr 2002, 34:9-17.
95. Kim H.J., Jung K.J., Yu B.P., Cho C.G., Choi J.S., Chung H.Y. Modulation of redox-sensitive transcription factors by calorie restriction during aging. Mech Ageing Dev 2002, 123:1589-1595.
96. Yen W.L., Klionsky D.J. How to live long and prosper: autophagy, mitochondria, and aging. Physiology (Bethesda) 2008, 23:248-262.
97. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721.
98. Mizushima N. Autophagy: process and function. Genes Dev 2007, 21:2861-2873.
99. Lee I.H., Cao L., Mostoslavsky R., et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 2008, 105:3374-3379.
100. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
101. Weichhart T. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods Mol Biol 2012, 821:1-14.
102. Johnson S.C., Rabinovitch P.S., Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
103. Ghosh H.S., McBurney M., Robbins P.D. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS ONE 2010, 5:e9199.
104. Ou X., Lee M.R., Huang X., Messina-Graham S., Broxmeyer H.E. SIRT1 positively regulates autophagy and mitochondria function in embryonic stem cells under oxidative stress. Stem Cells 2014, 32:1183-1194.
105. Takeda-Watanabe A., Kitada M., Kanasaki K., Koya D. SIRT1 inactivation induces inflammation through the dysregulation of autophagy in human THP-1 cells. Biochem Biophys Res Commun 2012, 427:191-196.
106. Kanfi Y., Naiman S., Amir G., et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012, 483:218-221.
107. Takasaka N., Araya J., Hara H., et al. Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence. J Immunol 2014, 192:958-968.
108. Talaei F., van Praag V.M., Henning R.H. Hydrogen sulfide restores a normal morphological phenotype in Werner syndrome fibroblasts, attenuates oxidative damage and modulates mTOR pathway. Pharmacol Res 2013, 74:34-44.
109. Suzuki M., Bartlett J.D. Sirtuin1 and autophagy protect cells from fluoride-induced cell stress. Biochim Biophys Acta 1842, 2014:245-255.
110. Hariharan N., Maejima Y., Nakae J., Paik J., Depinho R.A., Sadoshima J. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 2010, 107:1470-1482.
111. Colman R.J., Anderson R.M., Johnson S.C., et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
112. Fontana L. Calorie restriction and cardiometabolic health. Eur J Cardiovasc Prev Rehabil 2008, 15:3-9.
113. Guo Z., Mitchell-Raymundo F., Yang H., et al. Dietary restriction reduces atherosclerosis and oxidative stress in the aorta of apolipoprotein E-deficient mice. Mech Ageing Dev 2002, 123:1121-1131.
114. Ungvari Z., Parrado-Fernandez C., Csiszar A., de Cabo R. Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. Circ Res 2008, 102:519-528.
115. Weiss E.P., Fontana L. Caloric restriction: powerful protection for the aging heart and vasculature. Am J Physiol Heart Circ Physiol 2011, 301:H1205-H1219.
116. Cohen H.Y., Miller C., Bitterman K.J., et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
117. Stein S., Schafer N., Breitenstein A., et al. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice. Aging (Albany NY) 2010, 2:353-360.
118. Wood J.G., Rogina B., Lavu S., et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
119. Ungvari Z., Labinskyy N., Mukhopadhyay P., et al. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009, 297:H1876-H1881.
120. Juric D., Wojciechowski P., Das D.K., Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 2007, 292:H2138-H2143.
121. Gu X.S., Wang Z.B., Ye Z., et al. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet Mol Res 2014, 13:323-335.
122. Li Y.G., Zhu W., Tao J.P., et al. Resveratrol protects cardiomyocytes from oxidative stress through SIRT1 and mitochondrial biogenesis signaling pathways. Biochem Biophys Res Commun 2013, 438:270-276.
123. Liu Y.H., Lu M., Hu L.F., Wong P.T., Webb G.D., Bian J.S. Hydrogen sulfide in the mammalian cardiovascular system. Antioxid Redox Signal 2012, 17:141-185.
124. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
125. Dimmeler S., Nicotera P. MicroRNAs in age-related diseases. EMBO Mol Med 2013, 5:180-190.
126. Olivieri F., Rippo M.R., Procopio A.D., Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. Front Genet 2013, 4:121.
127. Boon R.A., Iekushi K., Lechner S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013, 495:107-110.
128. Jansen F., Yang X., Nickenig G., Werner N., Vasa-Nicotera M. Role, function and therapeutic potential of microRNAs in vascular aging. Curr Vasc Pharmacol 2013.
129. Ito T., Yagi S., Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun 2010, 398:735-740.
130. Kawashima T., Inuzuka Y., Okuda J., et al. Constitutive SIRT1 overexpression impairs mitochondria and reduces cardiac function in mice. J Mol Cell Cardiol 2011, 51:1026-1036.
131. Li Y., Xu W., McBurney M.W., Longo V.D. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab 2008, 8:38-48.